Skip to main
LFCR
LFCR logo

LFCR Stock Forecast & Price Target

LFCR Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Lifecore Biomedical Inc. is poised for growth, evidenced by an increase in EBITDA from $22.6 million with a 16.8% margin in FY26 to an anticipated $27.3 million with a 19.1% margin in FY27. Additionally, the company has successfully transitioned to positive free cash flow, projecting $5.1 million in FY26, which is expected to rise to $6.0 million in FY27. This combination of expanding margins and strengthening cash flow underlines a robust financial outlook for Lifecore Biomedical.

Bears say

Lifecore Biomedical Inc faces a challenging financial outlook due to an anticipated decline in market growth for fill/finish services, projected to be lower than the company's stated 10% growth assumption. Additionally, the company is experiencing a high leverage ratio, which further complicates its financial position and suggests increased risk. These factors, combined with a lack of meaningful revenue growth expected until calendar year 2027, justify a cautious perspective on the company's stock performance compared to its peers.

LFCR has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lifecore Biomedical Inc (LFCR) Forecast

Analysts have given LFCR a Buy based on their latest research and market trends.

According to 2 analysts, LFCR has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lifecore Biomedical Inc (LFCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.